| 1/13/2021 The purpose of this Funding Opportunity Announcement is to promote the development of prognostic, monitoring, and diagnostic biomarkers for diabetic foot ulcers that can be used in clinical trials and patient care. This initiative would support early analytical and clinical validation of biomarkers through a phased award to encourage innovative research. The initiative would leverage the resources of the Diabetic Foot Consortium to facilitate the access to well-characterized patients and high-quality human samples. The goal of this initiative is to deliver candidate biomarkers that are ready for definitive analytical and clinical validation studies through the Diabetic Foot Consortium. Teresa L.Z. Jones, M.D. | RFA-DK-21-001 1/11/2021 This Funding Opportunity Announcement (FOA) invites applications for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently outlined by the NIH Office of AIDS Research (OAR) in NOT-20-018, UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding, scientific priorities. Potential topics could address multiple overarching priorities. These include elucidation of unique pathophysiological mechanisms contributing to HIV comorbidities, coinfections, and complications (CCCs) affecting organs, tissues, and processes within the mission of the NIDDK. Likewise, interrogations into biological mechanisms underlying HIV reservoirs in NIDDK-relevant tissues are important for developing strategies for long-term viral suppression or eradication. Finally, health-impeding social determinants of health may affect CCCs or viral reservoirs within NIDDK's mission through multiple pathways. Peter J. Perrin, Ph.D.; Deepak Nihalani, Ph.D.; Saul Malozowski, M.D., Ph.D., M.B.A. | PAR-21-062 1/8/2021 This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Peter J. Perrin, Ph.D.; Deepak Nihalani, Ph.D.; Saul Malozowski, M.D., Ph.D., M.B.A. | PAS-21-031 1/7/2021 The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES. Henry B. Burch, M.D.; Christine G. Lee, M.D., M.S.; Barbara Linder, M.D., Ph.D.; Miranda Broadney, M.D., M.P.H.; Pamela L. Thornton, Ph.D. | RFA-DK-20-032 1/7/2021 Type 1 diabetes (T1D) is a serious and burdensome chronic disease that usually onsets in childhood or early adulthood. Recent progress in clinical trials and understanding of T1D pathogenesis and mechanisms have created opportunities to delay the onset and progression of the disease. This supplement is intended to provide resources for the design and conduct of new intervention studies in individuals at early pre-clinical stages of T1D and in individuals with new-onset T1D through the T1D TrialNet network (TrialNet). This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator of the TrialNet Coordinating Center (TNCC) that is currently supporting the research being performed by TrialNet. The TNCC provides TrialNet with scientific leadership in study design and monitoring, supports the clinical and laboratory testing for the conduct of trials, and supports systems for data collection, processing, biostatistical analyses and administrative operations. Ellen Leschek, M.D. | RFA-DK-20-508 1/6/2021 The goal of this funding opportunity is to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease (CVD) among individuals with Type 1 Diabetes Mellitus (T1DM), and support the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic studies to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM. The focus of this FOA is on macrovascular disease that includes outcomes of myocardial infarction, stroke, peripheral artery disease, heart failure, cardiomyopathy, cardiac arrythmias and cardiac autonomic neuropathy and/or the study of coronary arteries, cerebral arteries, large peripheral arteries, cardiac tissue, atherosclerosis, thrombosis and lipoprotein metabolism. Research can include the effect of microvascular disease on the development of macrovascular disease, e.g., DKD, but the emphasis must be on CVD. Teresa L.Z. Jones, M.D. | RFA-HL-21-014 | 
No comments:
Post a Comment